Atrium Therapeutics, Inc. (RNA) stock
RNANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 12, 2026
$6.64+0.16 (+2.47%)
Close on Nov 18, 2026Market cap $113.58MP/E –Yield –
Atrium Therapeutics operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$6.63M | – |
| Q2 FY2026 | Jun 30, 2026 | -$22.62M | – |
| Q1 FY2026 | Mar 31, 2026 | -$17.28M | – |
| Q3 FY2025 | Sep 30, 2025 | -$213.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$12.86M | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.45M | – |
See a number that looks wrong?